DRTS Alpha Tau Medical Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2023

 

Commission File Number: 001-41316

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ☐

 

CONTENTS

 

On August 24, 2023, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Medical to Participate in September Investor Conferences.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

The information in this Report on Form 6-K, including in Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release dated August 24, 2023.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Alpha Tau Medical Ltd.
Date: August 24, 2023	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

 

 

Exhibit 99.1

 

 

Alpha Tau Medical to Participate in September Investor Conferences

 

JERUSALEM, August 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.

 

Event:	Citi’s 2023 Annual BioPharma Conference
Format:	1-on-1 meetings
Date:	September 6th, 2023
Location:	Boston, MA

 

Event:	Emerging Growth Conference
Format:	Company presentation and 1-on-1 meetings
Date:	September 7th, 2023
Time	2:20 – 2:50 PM ET
Location:	Virtual

 

 

Event:	Cantor Fitzgerald Global Healthcare Conference
Format:	Fireside chat and 1-on-1 meetings
Date:	September 27th, 2023
Time:	3:35 – 4:05 PM ET
Location:	New York, NY

 

Please reach out to your Citi and Cantor representatives to schedule, and register here to ensure you are able to attend the Emerging Growth conference and receive any updates that are released.

https://goto.webcasts.com/starthere.jsp?ei=1603285&tp_key=ab3efc5870&sti=drts

 

If attendees are not able to join the Emerging Growth Conference live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.

 

About Alpha Tau Medical, Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

 

Investor Relations Contact:
IR@alphatau.com

---